ExploreWatchlistsPricing
  1. JP-listed companies
  2. Sumitomo Pharma Co., Ltd.
  3. Financials
  4. Cash and cash equivalents

Sumitomo Pharma Co., Ltd. (4506)

Market cap
¥546.9B
P/E ratio
8x
Sumitomo Pharma manufactures and sells prescription pharmaceuticals globally, with specialized focus on regenerative and cell medicine through joint ventures.
SummaryFinancialsDividendsHistorySegmentsOwnershipWorkforce
Period EndCash and cash equivalents (Million JPY)YoY (%)
Mar 31, 202644,310+91.69%
Mar 31, 202523,116-20.42%
Mar 31, 202429,047-79.76%
Mar 31, 2023143,478-29.32%
Mar 31, 2022202,984+4.79%
Mar 31, 2021193,698+90.45%
Mar 31, 2020101,708-25.92%
Mar 31, 2019137,296+73.35%
Mar 31, 201879,201+10.91%
Mar 31, 201771,408+30.02%
Mar 31, 201654,922+79.76%
Mar 31, 201530,553

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat